An IB, Byun MS, Yang SI, et al. - Only limited therapeutic benefits have been attained from GLP‐1 receptor agonists (GLP‐1 RAs) despite their attractiveness as novel antidiabetic agents; this is related to common drug nonadherence mainly due to side effects such as nausea, vomiting, and abdominal pain. Considering that GLP‐1 receptor density differs throughout the organs, researchers tried binding modulation to change receptor binding mechanism for the invention of novel GLP‐1 RAs with better safety profile. A novel glycosylated Fc‐fused GLP‐1 RA (GLP‐1‐gFc) was constructed and binding affinity and potency were determined using in‐vitro instrumental and cell‐based analyses. Then they performed in‐vivo comparison of glucose‐lowering and side effects between GLP‐1‐gFc and dulaglutide. In the phase 1 clinical trial, the efficacy and safety profile of GLP‐1‐gFc were examined. Outcomes analyses suggest the possible value GLP‐1‐gFc as a novel GLP‐1 RA with better safety than dulaglutide to enhance therapeutic benefits in individuals with type 2 diabetes.